Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc.TRAX · Entity 4696 | Chief Financial Officer | May 12, 2026 | May 14, 2026 |
| Monte Rosa Therapeutics, Inc.GLUE · Entity 4828 | Chief Financial Officer | January 03, 2023 | January 04, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
First Tracks Biotherapeutics, Inc.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 5,000 |
Reported balance
After 2026-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 5,000 · Balance 5,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2: The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.81 · Expires 2036-05-11 | Direct | 13,600 |
Reported balance
After 2026-05-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-12 · Grant · Acquired 13,600 · Balance 13,600 F3: The stock option vests as to 25% of the total shares on May 12, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4: In addition to the options to purchase a total of 13,600 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 123,700 shares of common stock, which options vest according to their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2: The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3: The stock option vests as to 25% of the total shares on May 12, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F4: In addition to the options to purchase a total of 13,600 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 123,700 shares of common stock, which options vest according to their terms.
Monte Rosa Therapeutics, Inc.
Report date January 03, 2023 · Filed January 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2033-01-02 | Direct | 129,850 |
Reported balance
After 2023-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 129,850 · Balance 129,850 F1: 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 14, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantEmployee Stock Option (right to buy) · Derivative | 13,600 | $0.00 Strike: $17.81 | $0.00 |
DisclosureSEC source: 0001855684-26-000008 · form4-05142026_040503.xml · derivative · entry 2 Tamboli Ajim · CIK 0001855684 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,600 Underlying: Common Stock · 13,600 shares Expires 2036-05-11 F3 · derivative.exercise_date: The stock option vests as to 25% of the total shares on May 12, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · balance_after: In addition to the options to purchase a total of 13,600 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 123,700 shares of common stock, which options vest according to their terms. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001855684-26-000008 · form4-05142026_040503.xml · derivative · entry 1 Tamboli Ajim · CIK 0001855684 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 22:08 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantEmployee Stock Option (right to buy) · Derivative | 41,234 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001855684-26-000007 · form4-04232026_100450.xml · derivative · entry 4 Tamboli Ajim · CIK 0001855684 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,234 Underlying: Common Stock · 41,234 shares Expires 2036-04-22 F3 · derivative.exercise_date: The stock option vests as to 25% of the total shares on April 20, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 22, 2026 Filed Apr 23, 2026 22:08 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantEmployee Stock Option (right to buy) · Derivative | 41,233 | $0.00 Strike: $18.87 | $0.00 |
DisclosureSEC source: 0001855684-26-000007 · form4-04232026_100450.xml · derivative · entry 3 Tamboli Ajim · CIK 0001855684 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,233 Underlying: Common Stock · 41,233 shares Expires 2036-04-21 F3 · derivative.exercise_date: The stock option vests as to 25% of the total shares on April 20, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 22:08 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantEmployee Stock Option (right to buy) · Derivative | 41,233 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001855684-26-000007 · form4-04232026_100450.xml · derivative · entry 2 Tamboli Ajim · CIK 0001855684 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,233 Underlying: Common Stock · 41,233 shares Expires 2036-04-20 F3 · derivative.exercise_date: The stock option vests as to 25% of the total shares on April 20, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 22:08 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 45,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001855684-26-000007 · form4-04232026_100450.xml · derivative · entry 1 Tamboli Ajim · CIK 0001855684 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,700 Underlying: Common Stock · 45,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 1/4 of the RSUs shall vest on April 20, 2027 and 1/4th of the RSUs shall vest in equal annual installments until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: 1/4 of the RSUs shall vest on April 20, 2027 and 1/4th of the RSUs shall vest in equal annual installments until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:30 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 129,850 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-23-000951 · doc4.xml · derivative · entry 1 Tamboli Ajim · CIK 0001855684 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,850 Underlying: Common Stock · 129,850 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:47 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 111,700 | $0.00 Strike: $13.41 | $0.00 |
DisclosureSEC source: 0000899243-22-008707 · doc4.xml · derivative · entry 1 Tamboli Ajim · CIK 0001855684 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,700 Underlying: Common Stock · 111,700 shares Expires 2032-02-29 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 21:01 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 56,649 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-21-025983 · doc4.xml · derivative · entry 2 Tamboli Ajim · CIK 0001855684 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,649 Underlying: Common Stock · 56,649 shares Expires 2031-06-22 F4 · derivative.exercise_date: 25% of this option shall vest and become exercisable on May 28, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 12, 2021 Filed Jun 25, 2021 21:01 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 100,938 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0000899243-21-025983 · doc4.xml · derivative · entry 1 Tamboli Ajim · CIK 0001855684 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,938 Underlying: Common Stock · 100,938 shares Expires 2031-04-12 F1 · derivative.exercise_price: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on April 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. F1 · derivative.underlying_shares: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F1 · balance_after: On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.